IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2422
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$5.7B
Michael S. Weiss
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = TGTX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$TGTX TG THERAPEUTICS, INC. | 47 | 64 | 59 | 42 | 10.9x | 55.0x | 70.5% | 41.8% | 86.3% | 16.2% | 67.6% | 120.1% | 0.0% | 69.0x | $5.7B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
TG THERAPEUTICS, INC. (TGTX) receives a "Reduce" rating with a composite score of 47.4/100. It ranks #2422 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Michael S. Weiss
Chief Executive Officer
Labor Force
290
64
23
73
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for TGTX
In-line with peers — no strong momentum signal
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for TGTX.
View All RatingsImproving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
ROIC 17.1% vs WACC 9.4% (spread +7.7%)
GM 86% vs sector 43%, OM 16% vs sector 1%
Capital turnover 0.94x, R&D intensity 28.1%
Rev growth 120%, 10yr history
Interest coverage 4.4x, Net debt/EBITDA 5.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
TG THERAPEUTICS, INC. receives a Reduce rating from our analysis, with a composite score of 47.4/100 and 2 out of 5 stars, ranking #2422 out of 7,333 stocks. TGTX's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 64/100, TGTX shows adequate but unremarkable business quality. The company reports a return on equity of 70.5% (sector avg: -2.5%), gross margins of 86.3% (sector avg: 42.5%), net margins of 67.6% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
TGTX's value score of 59/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 10.95x, an EV/EBITDA of 54.98x, a P/B ratio of 7.72x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
TG THERAPEUTICS, INC.'s investment score of 23/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 120.1% vs. a sector average of 5.9% and a return on assets of 41.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
TGTX is currently showing below-average momentum at 42/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 120.1% year-over-year, while a beta of 0.47 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
TGTX shows good financial stability with a score of 73/100. Key stability metrics include a beta of 0.47 and a debt-to-equity ratio of 69.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
TG THERAPEUTICS, INC.'s short interest score of 14/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 69.00x). At $5.7B (mid-cap), TGTX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
TG THERAPEUTICS, INC. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2422 of 7,333 overall (67th percentile). Key comparisons include ROE of 70.5% exceeding the -2.5% sector median and operating margins of 16.2% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TGTX currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (14) would have the largest impact on the composite score.
EV/EBITDA 380% ABOVE SECTOR MEDIAN
ROE 2942% BELOW SECTOR MEDIAN
Gross Margin 103% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate TG THERAPEUTICS, INC. (TGTX) as a Reduce with a composite score of 47.4/100 at a current price of $30.49. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (73th percentile) and quality (64th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (23th percentile) and momentum (42th percentile) tempers our overall conviction. We assign a Narrow Moat rating (54/100), Low uncertainty, and Exemplary capital allocation.
Key items to watch: sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
TG THERAPEUTICS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 47.4/100 places it at rank #2422 in our full 7,333-stock universe. At $5.7B in market capitalization, TG THERAPEUTICS, INC. is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 120%, though momentum at the 42th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 86% (+43.8pp vs sector) narrow to operating margins of 16% (+14.9pp vs sector) and net margins of 67.6%, yielding a gross-to-net conversion rate of 78%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $30.49, TG THERAPEUTICS, INC. is trading near fair value based on current fundamentals. Our value factor score of 59/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 10.9x (a 51% discount to the sector median of 22.3x), EV/EBITDA of 55.0x (at a premium), P/B of 7.7x, P/S of 9.2x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Gross margins of 86% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 70.5% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 120% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Return on assets of 41.8% indicates efficient deployment of the full asset base, not just equity capital.
The Reduce rating (composite 47.4/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
We assign a Low uncertainty rating to TG THERAPEUTICS, INC.. The company exhibits strong financial stability with a beta of 0.47, and a stability factor in the 73th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.47 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 73th percentile and quality factor at the 64th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 86% provide a buffer against cost pressures; above-average stability (73th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate TG THERAPEUTICS, INC.'s capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 70.5%, best-in-class net margins of 67.6%. Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — TG THERAPEUTICS, INC. meets this high bar.
The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. We note that the combination of 41.8% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.
In summary, TG THERAPEUTICS, INC. receives a Reduce rating with a composite score of 47.4/100 (rank #2422 of 7,333). Our quantitative framework assigns a Narrow Moat (54/100, trend: stable), Low uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 52/100.
Our analysis does not support a constructive view on TG THERAPEUTICS, INC. at this time. The combination of the current quantitative profile, low uncertainty, and exemplary capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign TG THERAPEUTICS, INC. a Narrow Moat rating with a composite moat score of 54/100. The ROIC-WACC spread of +7.7% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that TG THERAPEUTICS, INC. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 18.9/20.
The strongest moat sources are margin superiority (18.9/20) and growth durability (15/20). GM 86% vs sector 43%, OM 16% vs sector 1%. Rev growth 120%, 10yr history. These pillars form the core of TG THERAPEUTICS, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (3/20) and reinvestment efficiency (8.1/20). Interest coverage 4.4x, Net debt/EBITDA 5.8x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect TG THERAPEUTICS, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 86% providing a solid profitability foundation, operating margins of 16% reflecting effective cost management, robust top-line growth of 120% expanding the revenue base. The margin cascade from 86% gross to 16% operating to 67.6% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 64th percentile.
The margin profile shows gross margins of 86%, operating margins of 16%, net margins of 67.6%. Return metrics include ROE of 70.5% and ROA of 41.8%. Relative to the Manufacturing sector, gross margins are 43.8 percentage points above the sector median of 43%, and ROE of 70.5% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 69%, revenue growth of 120%. The sector median D/E is 0%, putting TG THERAPEUTICS, INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trading. Notable movers include Wells Fargo reporting earnings, BP announcing a $5 billion writedown in energy transition businesses, WeRide launching a robotaxi service on WeChat, and TG Therapeutics providing optimistic 2026 guidance.
TG Therapeutics, listed as NasdaqCM:TGTX, released five year data for BRIUMVI in relapsing multiple sclerosis. The ULTIMATE I & II open label extension results show durable efficacy, low relapse rates, and consistent safety over the full study period. The company highlighted long term treatment adherence and improved patient outcomes as key takeaways from the new dataset. TG Therapeutics focuses on developing and commercializing treatments for serious autoimmune and B cell mediated...
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ETNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-80
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of long term/five-year data from the ongoing open-label extension (OLE) of the Pha